CJ Bioscience Inc, formerly ChunLab Inc, is a Korea-based company principally engaged in the provision of microbial bioinformatics platform and solutions. The Company mainly provides microbial bioinformatics analysis services and microbiome-based healthcare services through bioinformatics database and cloud analytics platform. The Company also develops microbiome therapies and infection diagnosis solutions.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	₩3,650.00	+0.27%	2,504
27/10/26	₩3,640.00	-1.22%	6,124
26/10/26	₩3,685.00	+2.22%	17,739
23/10/26	₩3,605.00	-2.30%	8,276
22/10/26	₩3,690.00	-2.25%	4,513

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 28/10/2026			5-day change	1st Jan Change
3,650.00 ^KRW	+0.27%		-3.31%	-60.84%

08-14	CJ Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
02-26	CJ BIO Announces the Publication of Clinical Research Findings on Its Postbiotic Ingredient, BiomeNrich Post SZ075	CI

Market Cap	47.69B 35.48M 31.83M 29.43M 26.65M 49.79M 3.38B 50.39M 352M 140M 1.77B 133M 130M 5.61B	P/E 2024	-2.85x	P/E 2025	-5.07x
Enterprise Value	7.26B 5.4M 4.85M 4.48M 4.06M 7.58M 514M 7.67M 53.58M 21.34M 269M 20.27M 19.84M 855M	EV / Sales 2024	19x	EV / Sales 2025	22x
Free-Float	38.05%	Yield 2024 *	-	Yield 2025	-

08-14	CJ Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
02-26	CJ BIO Announces the Publication of Clinical Research Findings on Its Postbiotic Ingredient, BiomeNrich Post SZ075	CI
18/02/25	Cj Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate Cjrb-201 At 'Ecco2025'	CI
17/12/24	CJ Bioscience, Inc. announced that it has received KRW 40.00000224 billion in funding from CJ Cheiljedang Corporation	CI
09/12/24	CJ Bioscience, Inc. announced that it expects to receive KRW 40.00000224 billion in funding from CJ Cheiljedang Corporation	CI
10/08/23	CJ Bioscience, Inc. announced that it has received KRW 24.033 billion in funding from CJ Cheiljedang Corporation	CI
15/05/23	CJ Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
01/03/23	Provectus Algae Pty Ltd announced that it has received funding from CJ Bioscience, Inc.	CI
08/11/21	CJ Bioscience, Inc. agreed to acquire Red BIO business of CJ Cheiljedang Corporation for KRW 6.1 billion.	CI
29/10/21	CJ Cheiljedang Corporation completed the acquisition of 15.99% stake in ChunLab, Inc. from Jong-sik Cheon and Shanghai ZJ Bio-Tech Co., Ltd..	CI
29/10/21	ChunLab, Inc. announced that it has received KRW 73.24122766 billion in funding from CJ Cheiljedang Corporation	CI
21/07/21	CJ Cheiljedang Corporation signed a stock purchase contract to acquire 15.99% stake in ChunLab, Inc. from Jong-sik Cheon and Shanghai ZJ Bio-Tech Co., Ltd. for KRW 25 billion.	CI
21/07/21	ChunLab, Inc. announced that it expects to receive KRW 73.24122766 billion in funding from CJ Cheiljedang Corporation	CI

1 day	+0.27%
1 week	-3.31%
Current month	-1.48%
1 month	-2.41%
3 months	+7.04%
6 months	-54.55%
Current year	-60.84%

CJ Bioscience, Inc. Stock

Stocks

A311690

KR7311690002

Biotechnology & Medical Research

Valuation: CJ Bioscience, Inc.

Chart: CJ Bioscience, Inc.

Latest news: CJ Bioscience, Inc.

Press Releases: CJ Bioscience, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CJ Bioscience, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	3,595	3,945
1 month	3,515	4,035
Current year	3,060	9,420
1 year	3,060	10,200
3 years	3,060	18,800
5 years	3,060	55,100
10 years	3,060	73,000

Director	Title	Age	Since
Tae-Hyeon Park BRD	Director/Board Member	69	-
Sang-Bae Yoon CHM	Chairman	56	14/08/2025
Ji-Won Seo BRD	Director/Board Member	54	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CJ BIOSCIENCE, INC.	+0.27%	-3.31%	-61.42%	-72.18%	35.48M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	64.14B
ARGENX SE	+1.21%	+2.88%	+12.48%	+84.27%	55.53B
LONZA GROUP AG	+1.30%	+1.53%	+12.77%	+104.75%	53.03B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	45.99B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	42.45B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	40.45B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.25B
GENMAB A/S	-1.76%	+43.18%	+104.41%	+90.86%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-0.44%	+23.18%	-10.77%	24.23B
Average	+0.56%	+3.56%	+40.97%	+139.12%	39.26B
Weighted average by Cap.	+0.85%	+3.49%	+49.36%	+160.51%

	2024	2025
Net sales	3.47B 2.58M 2.31M 2.14M 1.94M 3.62M 246M 3.66M 25.58M 10.19M 129M 9.68M 9.47M 408M	3.69B 2.75M 2.46M 2.28M 2.06M 3.86M 262M 3.9M 27.24M 10.85M 137M 10.31M 10.09M 435M
Net income	-32.84B -24.43M -21.92M -20.26M -18.35M -34.29M -2.33B -34.7M -242M -96.5M -1.22B -91.67M -89.73M -3.86B	-24B -17.86M -16.02M -14.81M -13.42M -25.06M -1.7B -25.37M -177M -70.54M -890M -67.01M -65.6M -2.83B
Net Debt	-65.96B -49.07M -44.02M -40.7M -36.86M -68.87M -4.67B -69.7M -487M -194M -2.45B -184M -180M -7.76B	-40.43B -30.07M -26.98M -24.95M -22.59M -42.21M -2.86B -42.72M -298M -119M -1.5B -113M -110M -4.76B